Seres Therapeutics (MCRB) Stock Declines in Second Day of Trading

NEW YORK (TheStreet) -- Seres Therapeutics (MCRB) shares closed trading down 25.70% to $38.19 in the second day of trading since the company's upsized initial public offering on Friday.

The Cambridge, MA-based company priced its upsized public offering of 7.43 million shares at $18 per share on Friday before closing trading up 68% to $50.49.

The company had previously said that it would offer 6.25 million shares between the $15 and $17 per share range.

Seres Therapeutics' lead development candidate, SER-109, is an oral therapeutic for the prevention of Clostridium difficile infection which affects between 85,000 and 110,000 people in the U.S.

The drug candidate is currently in Phase II trials.

MCRB Price Chart MCRB Price data by YCharts

If you liked this article you might like

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Rigel Rises on Update on FDA Review of Bleeding Disorder Treatment

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Premarket Biotech Movers: Mylan, Momenta Pharmaceuticals, Seres Therapeutics

Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics

Jim Cramer's Top Takeaways: Anadarko Petroleum, Coach, Seres Therapeutics

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Jim Cramer's 'Mad Money' Recap: Are You Ready to Make Your Move?

Seres Therapeutics (MCRB) Stock Surges, FBR Capital Remains Bullish

Seres Therapeutics (MCRB) Stock Surges, FBR Capital Remains Bullish